240 related articles for article (PubMed ID: 25398847)
21. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
[TBL] [Abstract][Full Text] [Related]
22. Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells.
Sawada T; Watanabe M; Fujimura Y; Yagishita S; Shimoyama T; Maeda Y; Kanda S; Yunokawa M; Tamura K; Tamura T; Minami H; Koh Y; Koizumi F
Cancer Sci; 2016 Mar; 107(3):307-14. PubMed ID: 26708016
[TBL] [Abstract][Full Text] [Related]
23. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
24. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
25. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
[TBL] [Abstract][Full Text] [Related]
26. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
27. The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
Azizi Tabesh G; Izadi P; Fereidooni F; Emami Razavi AN; Tavakkoly Bazzaz J
Cancer Invest; 2017 Jan; 35(1):36-42. PubMed ID: 27901576
[TBL] [Abstract][Full Text] [Related]
28. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
29. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
Ramirez AB; Bhat R; Sahay D; De Angelis C; Thangavel H; Hedayatpour S; Dobrolecki LE; Nardone A; Giuliano M; Nagi C; Rimawi M; Osborne CK; Lewis MT; Stilwell JL; Kaldjian EP; Schiff R; Trivedi MV
BMC Cancer; 2019 Mar; 19(1):220. PubMed ID: 30871481
[TBL] [Abstract][Full Text] [Related]
31. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Abramson VG; Cooper Lloyd M; Ballinger T; Sanders ME; Du L; Lai D; Su Z; Mayer I; Levy M; LaFrance DR; Vnencak-Jones CL; Shyr Y; Dahlman KB; Pao W; Arteaga CL
Breast Cancer Res Treat; 2014 Jun; 145(2):389-99. PubMed ID: 24722917
[TBL] [Abstract][Full Text] [Related]
32. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
[TBL] [Abstract][Full Text] [Related]
33. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
34. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
Higgins MJ; Jelovac D; Barnathan E; Blair B; Slater S; Powers P; Zorzi J; Jeter SC; Oliver GR; Fetting J; Emens L; Riley C; Stearns V; Diehl F; Angenendt P; Huang P; Cope L; Argani P; Murphy KM; Bachman KE; Greshock J; Wolff AC; Park BH
Clin Cancer Res; 2012 Jun; 18(12):3462-9. PubMed ID: 22421194
[TBL] [Abstract][Full Text] [Related]
35. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
36. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
[TBL] [Abstract][Full Text] [Related]
37. Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer.
Cardinali B; De Luca G; Tasso R; Coco S; Garuti A; Buzzatti G; Sciutto A; Arecco L; Villa F; Carli F; Reverberi D; Quarto R; Dono M; Del Mastro L
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682999
[TBL] [Abstract][Full Text] [Related]
38. A novel PIK3CA hotspot mutation in Isfahanian breast cancer patients.
Gharbi S; Faghihi M; Tavassoli M
Cancer Invest; 2011 May; 29(4):313-7. PubMed ID: 21345071
[TBL] [Abstract][Full Text] [Related]
39. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
